EPO and amyloidosis: Chronic treatment with cTfRMAb-EPO did not prevent the small but significant hippocampal neuronal loss in the PS19 mice (Figure 4), despite its therapeutic effects in reducing hippocampal pTau (Figure 2) and despite our previous work showing an improvement in neuronal health with this BBB-penetrating EPO in an APP/PSEN1 mouse model of amyloidosis [15].